Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in graves' orbital fibroblasts: inhibition by an IGF-I receptor blocking antibody.

Kumar S, Iyer S, Bauer H, Coenen M, Bahn RS.

J Clin Endocrinol Metab. 2012 May;97(5):1681-7. doi: 10.1210/jc.2011-2890. Epub 2012 Mar 7.

2.

A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy.

Turcu AF, Kumar S, Neumann S, Coenen M, Iyer S, Chiriboga P, Gershengorn MC, Bahn RS.

J Clin Endocrinol Metab. 2013 May;98(5):2153-9. doi: 10.1210/jc.2013-1149. Epub 2013 Mar 12.

3.
4.

A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves' ophthalmopathy.

Kumar S, Nadeem S, Stan MN, Coenen M, Bahn RS.

J Mol Endocrinol. 2011 Apr 12;46(3):155-63. doi: 10.1530/JME-11-0006. Print 2011 Jun.

5.
6.

Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves' disease immunoglobins.

Krieger CC, Neumann S, Place RF, Marcus-Samuels B, Gershengorn MC.

J Clin Endocrinol Metab. 2015 Mar;100(3):1071-7. doi: 10.1210/jc.2014-3566. Epub 2014 Dec 8.

7.

PDGF enhances orbital fibroblast responses to TSHR stimulating autoantibodies in Graves' ophthalmopathy patients.

van Steensel L, Hooijkaas H, Paridaens D, van den Bosch WA, Kuijpers RW, Drexhage HA, van Hagen PM, Dik WA.

J Clin Endocrinol Metab. 2012 Jun;97(6):E944-53. doi: 10.1210/jc.2012-1020. Epub 2012 Mar 21.

PMID:
22438231
8.

Effects of thyrotropin and thyrotropin-receptor-stimulating Graves' disease immunoglobulin G on cyclic adenosine monophosphate and hyaluronan production in nondifferentiated orbital fibroblasts of Graves' ophthalmopathy patients.

van Zeijl CJ, Fliers E, van Koppen CJ, Surovtseva OV, de Gooyer ME, Mourits MP, Wiersinga WM, Miltenburg AM, Boelen A.

Thyroid. 2010 May;20(5):535-44. doi: 10.1089/thy.2009.0447.

PMID:
20384487
9.

TSH-Mediated TNFα Production in Human Fibrocytes Is Inhibited by Teprotumumab, an IGF-1R Antagonist.

Chen H, Shan SJ, Mester T, Wei YH, Douglas RS.

PLoS One. 2015 Jun 18;10(6):e0130322. doi: 10.1371/journal.pone.0130322. eCollection 2015.

10.

Adipose tissue depot-specific differences in the regulation of hyaluronan production of relevance to Graves' orbitopathy.

Zhang L, Grennan-Jones F, Lane C, Rees DA, Dayan CM, Ludgate M.

J Clin Endocrinol Metab. 2012 Feb;97(2):653-62. doi: 10.1210/jc.2011-1299. Epub 2011 Dec 7.

PMID:
22162480
11.

Thyrotropin receptor-stimulating Graves' disease immunoglobulins induce hyaluronan synthesis by differentiated orbital fibroblasts from patients with Graves' ophthalmopathy not only via cyclic adenosine monophosphate signaling pathways.

van Zeijl CJ, Fliers E, van Koppen CJ, Surovtseva OV, de Gooyer ME, Mourits MP, Wiersinga WM, Miltenburg AM, Boelen A.

Thyroid. 2011 Feb;21(2):169-76. doi: 10.1089/thy.2010.0123. Epub 2010 Oct 18.

PMID:
20954819
12.

Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves' ophthalmopathy.

Dik WA, Virakul S, van Steensel L.

Exp Eye Res. 2016 Jan;142:83-91. doi: 10.1016/j.exer.2015.02.007. Review.

PMID:
26675405
13.

Possible targets for nonimmunosuppressive therapy of Graves' orbitopathy.

Zhang L, Grennan-Jones F, Draman MS, Lane C, Morris D, Dayan CM, Tee AR, Ludgate M.

J Clin Endocrinol Metab. 2014 Jul;99(7):E1183-90. doi: 10.1210/jc.2013-4182. Epub 2014 Apr 23.

PMID:
24758182
14.

Autoimmunity in Graves' ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors?

Wiersinga WM.

J Clin Endocrinol Metab. 2011 Aug;96(8):2386-94. doi: 10.1210/jc.2011-0307. Epub 2011 Jun 15. Review.

PMID:
21677036
15.

Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes.

Chen H, Mester T, Raychaudhuri N, Kauh CY, Gupta S, Smith TJ, Douglas RS.

J Clin Endocrinol Metab. 2014 Sep;99(9):E1635-40. doi: 10.1210/jc.2014-1580. Epub 2014 May 30.

16.

Immunopathogenesis of Graves' ophthalmopathy: the role of the TSH receptor.

Iyer S, Bahn R.

Best Pract Res Clin Endocrinol Metab. 2012 Jun;26(3):281-9. doi: 10.1016/j.beem.2011.10.003. Review.

17.

Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves' ophthalmopathy.

van Steensel L, Paridaens D, Schrijver B, Dingjan GM, van Daele PL, van Hagen PM, van den Bosch WA, Drexhage HA, Hooijkaas H, Dik WA.

Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3091-8. doi: 10.1167/iovs.08-2443. Epub 2009 Feb 21.

PMID:
19234339
18.

Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy.

Smith TJ, Hegedüs L, Douglas RS.

Best Pract Res Clin Endocrinol Metab. 2012 Jun;26(3):291-302. doi: 10.1016/j.beem.2011.10.002. Review.

19.

Pentraxin-3 Is a TSH-Inducible Protein in Human Fibrocytes and Orbital Fibroblasts.

Wang H, Atkins SJ, Fernando R, Wei RL, Smith TJ.

Endocrinology. 2015 Nov;156(11):4336-44. doi: 10.1210/en.2015-1399. Epub 2015 Aug 19.

PMID:
26287404
20.

Complete inhibition of rhTSH-, Graves' disease IgG-, and M22-induced cAMP production in differentiated orbital fibroblasts by a low-molecular-weight TSHR antagonist.

van Zeijl CJ, van Koppen CJ, Surovtseva OV, de Gooyer ME, Plate R, Conti P, Karstens WJ, Timmers M, Saeed P, Wiersinga WM, Miltenburg AM, Fliers E, Boelen A.

J Clin Endocrinol Metab. 2012 May;97(5):E781-5. doi: 10.1210/jc.2011-2931. Epub 2012 Mar 14.

PMID:
22419705
Items per page

Supplemental Content

Write to the Help Desk